MX2022014309A - Compuestos de insulina acilada de accion temporal prolongada. - Google Patents
Compuestos de insulina acilada de accion temporal prolongada.Info
- Publication number
- MX2022014309A MX2022014309A MX2022014309A MX2022014309A MX2022014309A MX 2022014309 A MX2022014309 A MX 2022014309A MX 2022014309 A MX2022014309 A MX 2022014309A MX 2022014309 A MX2022014309 A MX 2022014309A MX 2022014309 A MX2022014309 A MX 2022014309A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- acylated insulin
- extended time
- time action
- insulin compounds
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Los compuestos descritos en la presente se refieren al tratamiento de la diabetes tipo I y/o tipo II y/o la hiperglucemia. Más particularmente, los compuestos descritos se refieren a compuestos de insulina acilada de acción temporal prolongada que reducen la glucosa en sangre, composiciones farmacéuticas que contienen tales compuestos, usos terapéuticos de tales compuestos y un compuesto intermediario usado para fabricar los compuestos de insulina acilada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063025463P | 2020-05-15 | 2020-05-15 | |
| PCT/US2021/032144 WO2021231676A1 (en) | 2020-05-15 | 2021-05-13 | Extended time action acylated insulin compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014309A true MX2022014309A (es) | 2022-12-07 |
Family
ID=78524979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014309A MX2022014309A (es) | 2020-05-15 | 2021-05-13 | Compuestos de insulina acilada de accion temporal prolongada. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230174609A1 (es) |
| EP (1) | EP4149516A1 (es) |
| JP (1) | JP7456007B2 (es) |
| KR (1) | KR20230009499A (es) |
| CN (1) | CN115867308A (es) |
| AU (1) | AU2021273262A1 (es) |
| BR (1) | BR112022022885A2 (es) |
| CA (1) | CA3177905A1 (es) |
| CL (1) | CL2022003187A1 (es) |
| CO (1) | CO2022016338A2 (es) |
| CR (1) | CR20220641A (es) |
| EC (1) | ECSP22087958A (es) |
| IL (1) | IL297976A (es) |
| MX (1) | MX2022014309A (es) |
| PE (1) | PE20230832A1 (es) |
| WO (1) | WO2021231676A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116162147B (zh) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
| CN115947822B (zh) * | 2022-07-04 | 2023-08-18 | 北京惠之衡生物科技有限公司 | 一种长效酰化胰岛素衍生物及其药物组合物和应用 |
| CN115894719B (zh) * | 2022-11-24 | 2023-10-20 | 武汉禾元生物科技股份有限公司 | 一种人血清白蛋白胰岛素偶联物及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5693609A (en) * | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| US6444641B1 (en) * | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| BR9813111A (pt) | 1997-10-24 | 2000-08-15 | Lilly Co Eli | Composições de insulina insolúveis |
| WO2017005765A1 (en) | 2015-07-06 | 2017-01-12 | Novo Nordisk A/S | Novel peptides and peptide derivatives and uses thereof |
| JOP20190273A1 (ar) * | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
-
2021
- 2021-05-13 WO PCT/US2021/032144 patent/WO2021231676A1/en active Application Filing
- 2021-05-13 CR CR20220641A patent/CR20220641A/es unknown
- 2021-05-13 AU AU2021273262A patent/AU2021273262A1/en active Pending
- 2021-05-13 CA CA3177905A patent/CA3177905A1/en active Pending
- 2021-05-13 KR KR1020227043481A patent/KR20230009499A/ko active Search and Examination
- 2021-05-13 IL IL297976A patent/IL297976A/en unknown
- 2021-05-13 EP EP21805284.3A patent/EP4149516A1/en active Pending
- 2021-05-13 CN CN202180049612.8A patent/CN115867308A/zh active Pending
- 2021-05-13 PE PE2022002656A patent/PE20230832A1/es unknown
- 2021-05-13 US US17/998,090 patent/US20230174609A1/en active Pending
- 2021-05-13 MX MX2022014309A patent/MX2022014309A/es unknown
- 2021-05-13 JP JP2022569032A patent/JP7456007B2/ja active Active
- 2021-05-13 BR BR112022022885A patent/BR112022022885A2/pt unknown
-
2022
- 2022-11-15 CO CONC2022/0016338A patent/CO2022016338A2/es unknown
- 2022-11-15 CL CL2022003187A patent/CL2022003187A1/es unknown
- 2022-11-15 EC ECSENADI202287958A patent/ECSP22087958A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230174609A1 (en) | 2023-06-08 |
| AU2021273262A1 (en) | 2022-12-08 |
| JP7456007B2 (ja) | 2024-03-26 |
| CL2022003187A1 (es) | 2023-03-03 |
| ECSP22087958A (es) | 2022-12-30 |
| CR20220641A (es) | 2023-01-19 |
| KR20230009499A (ko) | 2023-01-17 |
| BR112022022885A2 (pt) | 2022-12-20 |
| CA3177905A1 (en) | 2021-11-18 |
| PE20230832A1 (es) | 2023-05-19 |
| EP4149516A1 (en) | 2023-03-22 |
| WO2021231676A1 (en) | 2021-11-18 |
| CN115867308A (zh) | 2023-03-28 |
| JP2023526069A (ja) | 2023-06-20 |
| CO2022016338A2 (es) | 2022-11-29 |
| IL297976A (en) | 2023-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220641A (es) | Compuestos de insulina acilada de acción temporal prolongada | |
| PH12019502655A1 (en) | Acylated insulin compound | |
| NO20084919L (no) | Oksadiazolidindionforbindelse | |
| JOP20210201A1 (ar) | مركب لخفض جلوكوز الدم | |
| EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| PH12019501251A1 (en) | Novel phenyl propionic acid derivatives and uses thereof | |
| NZ592283A (en) | Combination of an insulin and the GLP-1 agonist AVE0010 | |
| MY152172A (en) | Therapeutic agent for diabetes | |
| BR112022013009A2 (pt) | Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina | |
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| PH12019501363A1 (en) | Insulin containing pharmaceutical compositions | |
| MX368387B (es) | A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22. | |
| MX2018002223A (es) | Derivados de insulina novedosos y usos medicos de los mismos. | |
| EA201201617A1 (ru) | Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы | |
| EA201691420A1 (ru) | Композиции енолазы 1 (eno1) и их применение | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| MX2023000398A (es) | Analogos de insulina novedosos y usos de estos. | |
| MX2021010988A (es) | Derivados de insulina sensibles a la glucosa. | |
| MX2020014262A (es) | Composicion farmaceutica que comprende un agente basico poco soluble. | |
| EA202192483A1 (ru) | Лекарственное средство и способ лечения или профилактики осложнений диабета с использованием этого лекарственного средства | |
| PH12020550050A1 (en) | Novel acylated insulin analogues and uses thereof | |
| MX2020008905A (es) | Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas. | |
| MX2022012033A (es) | Agente terapeutico para infeccion por coronavirus. | |
| MX2022011129A (es) | Composicion farmaceutica para la prevencion o el tratamiento de la diabetes y de enfermedades metabolicas asociadas a la misma. | |
| Korkmaz et al. | Toward to understanding the role of reactive molecules in bio-oxidative treatment modalities. |